Sanitas AB announces that Valeant Pharmaceuticals International, Inc. (“Valeant”) today, Wednesday 8th June 2011, has submitted applications to the Competition Council of the Republic of Lithuania and the Polish Office for Competition and Consumer Protection for clearance of the proposed transaction. As announced on 24th May 2011, the funds advised by Citi Venture Capital International (“CVCI”, through the legal entities Citigroup Venture Capital International Jersey Limited and Baltic Pharma Limited), Invalda AB (“Invalda”), Amber Trust II S.C.A. (“Amber”) and certain other persons (together the “Controlling Shareholders”), on 23rd May 2011, entered into a definitive share sale and purchase agreement for the sale of their entire 87.2% shareholding in Sanitas AB to Valeant.
More information is available at: http://www.sanitasgroup.com/index.php/news/news/the-signature-date-of-the-share-sale-and-purchase-agreement-has-been-corrected/11468.
A further announcement will be made when appropriate.